Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Grass Care Administrations for a Wonderful, Sound Yard - 2The most effective method to Shake Hands Expertly: A Bit by bit Guide
- 3Astrophotographer captures rare footage of the Hubble Telescope crossing the sun (video)
- 4Fundamental Archives for Beginning Your Business
- 5Civil rights leader Jesse Jackson hospitalized, family requests prayers
- Ancient Pompeii construction site reveals the process for creating Roman concrete
- The Meaning of Breaking the Pen's Nib in Death penalties
- Hamas set to elect new terror leader with Hayya, Mashaal in pole position
- 6 Famous Urban communities for Shopping on the planet
- SpaceX launches Italian Earth-observing satellite to orbit on the 1st mission of 2026 (video)
- The Best Games On the planet
- Slims down for Maintainable Weight reduction
- Barry Manilow reveals lung cancer diagnosis and plans to undergo surgery: 'It's pure luck' it was 'found so early'
- The 10 Most Compelling Forerunners in Innovation
